Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
636 participants
INTERVENTIONAL
2014-12-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open-label Safety Study in Adults With ADHD
NCT02160262
Dasotraline Pediatric ADHD Study
NCT02428088
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
NCT02734693
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
NCT03231800
Dasotraline Pediatric Extension Study
NCT02457819
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dasotraline 4 mg
Dasotraline 4 mg once daily
Dasotraline
Dasotraline 4 mg once daily
Dasotraline 6 mg
Dasotraline 6 mg once daily
Dasotraline
Dasotraline 6 mg once daily
Placebo
Placebo once daily
Placebo
Placebo once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dasotraline
Dasotraline 4 mg once daily
Dasotraline
Dasotraline 6 mg once daily
Placebo
Placebo once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5) criteria for a primary diagnosis of ADHD (inattentive, hyperactive, or combined subtype) established by a comprehensive psychiatric evaluation that reviews psychiatric criteria. Diagnosis is confirmed by Adult ADHD Clinical Diagnostic Scale (ACDS). Note: The diagnosis of ADHD and appropriateness of inclusion in the trial will be independently confirmed by external expert review. Experts will review diagnostic and other screening instruments for each subject and approval is required before a subject can be randomized. The Mini International Neuropsychiatric Interview (MINI) will be administered to confirm the absence of any other comorbid psychiatric disorders.
* Subject has an ADHD RS IV with adult prompts total score of ≥ 26 at screening and at Baseline.
* Subject has a CGI S score of ≥ 4 at screening and at Baseline.
* Subject has a negative breath alcohol test and a negative urine drug screen (UDS) for any illicit drug at screening.
* If the subject has a positive drug screen for ADHD medications (eg, amphetamine) at screening, the subject must have a negative repeat UDS at least 7 days before baseline.
* Subject is male or a non pregnant, non lactating female.
* Female subjects must have a negative serum pregnancy test at screening; females who are post menopausal (defined as at least 12 months of spontaneous amenorrhea) and those who have undergone hysterectomy or bilateral oophorectomy will be exempted from the pregnancy test.
* Female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use an effective and medically acceptable form of birth control, as defined in Section 10.4, throughout the study period. Note: Continued use of an effective and medically acceptable form of birth control is recommended for 30 days after study completion.
* Subject must have a stable living arrangement that allows for consistent participation for the full duration of the study.
* Subject must be able to comply with study medication administration and adhere to protocol requirements.
* Subject can read well enough to understand the informed consent form and other subject materials.
* Subjects must complete a practice trial for the TASS assessment at one timepoint during Screening.
Exclusion Criteria
* Subject has a psychiatric disorder other than ADHD that has been the primary focus of treatment at any time during the 12 months before screening.
* Subject has a past history of, or current presentation consistent with, bipolar disorder (including bipolar I and bipolar II), schizophrenia, schizoaffective disorder, or any other psychotic disorder; a personality disorder per DSM 5 criteria.
* Subject has a history of drug dependence or Substance Related Disorder (excluding nicotine and caffeine) within the 12 months before screening, as defined by DSM 5 criteria.
\-- Subject has Hamilton Anxiety Rating Scale (HAM A) total score ≥ 21 at screening and baseline.
* Subject has PSQI total score ≥ 8 at screening or baseline or moderate to severe insomnia as determined by the Investigator.
* Subject has a history of non-response (per clinician judgment) to two adequate treatment regimens of stimulant or non-stimulant treatment for ADHD.
* Subject has a history of epilepsy, seizures (except childhood febrile seizures), unexplained syncope or other unexplained blackouts (except single incident), or head trauma with loss of consciousness lasting more than 5 minutes, or a history of clinically significant multiple head traumas without loss of consciousness.
* Subject has an acute or chronic medical condition (other than ADHD) that in the opinion of the investigator could confound clinical assessments or interfere with the ability of the subject to participate in the study.
* Subject is currently taking or has taken within 6 weeks prior to screening an antidepressent medication; antipsychotic medication; or lithium (any lithium preparation or formulation).
* Subject is currently taking or has taken within the previous 6 months an anticonvulsant medication (eg, phenytoin, carbamazepine, lamotrigine, valproic acid); antipsychotic medication; or lithium (any lithium preparation or formulation).
* Subject is currently taking an alpha 2 adrenergic receptor agonist (including clonidine and guanfacine).
* Subject has a life-time history of a pattern of abuse or diversion of stimulants.
* Subject has a body mass index (BMI) less than 18 or greater than 35 kg/m2 at screening or baseline.
* Subject answers "yes" to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C SSRS assessment at screening (in the past month). Subjects who answer "yes" to this question must be referred to the Investigator for follow up evaluation.
* Subject has attempted suicide within 2 years before the screening period.
* Subject has history of positive test for Hepatitis B surface antigen or Hepatitis C antibody and has liver function test results at screening above the upper limit of normal (ULN) for the reference laboratory.
* Subject is known to have tested positive for human immunodeficiency virus (HIV).
* Subject has a clinically significant abnormality on screening evaluation including physical examination, vital signs, ECG, or laboratory tests that the Investigator considers to be inappropriate to allow participation in the study.
* The subject's screening ECG shows a corrected QT interval using Fridericia's formula (QTcF) of ≥ 450 msec for male subjects or ≥ 470 msec for female subjects. Eligibility will be based on the core laboratory ECG interpretation report.
* The subject's screening hematology results show an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value ≥ 2 times the ULN, or a blood urea nitrogen (BUN) value ≥ 1.5 times the ULN for the reference range.
* Subject has a history of allergic reaction or has a known or suspected sensitivity to any substance that is contained in the study medication formulation.
* Subject is currently participating or has participated in a clinical trial within the last 90 days or has participated in more than 2 clinical trials within the past year. This includes studies using marketed compounds or devices. Note: Subjects will be checked for multiple study enrollments by site staff.
* Subject has been incarcerated in a prison within 12 months prior to Screening.
* Subject has previously been randomized in a clinical trial of dasotraline.
* Subject is an investigational site staff member or the relative of an investigational site staff member.
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sumitomo Pharma America, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
SEP-289 Medical Director, MD
Role: STUDY_DIRECTOR
Sumitomo Pharma America, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NoesisPharma,LLC
Phoenix, Arizona, United States
Preferred Research Partners
Little Rock, Arkansas, United States
Southern California Research LLC
Beverly Hills, California, United States
Pharmacology Research Institute
Encino, California, United States
Collaborative Neuroscience Network, LLC
Garden Grove, California, United States
North County Clinical Research
Oceanside, California, United States
University ot California, San Francisco
San Francisco, California, United States
Elite Clinical Trials, Inc.
Wildomar, California, United States
MCB Clinical Research Centers, LLC
Colorado Springs, Colorado, United States
ConnecticutClinicalResearch
Cromwell, Connecticut, United States
CNS Clinical Research Group
Coral Springs, Florida, United States
Gulfcoast Clinical Research
Fort Myers, Florida, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
Florida Clinical Research Center, LLC
Maitland, Florida, United States
Miami Research Associates
Miami, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
Meridien Research
Tampa, Florida, United States
The Institute for Advanced Medical Research
Alpharetta, Georgia, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
iResearch Atlanta, LLC
Decatur, Georgia, United States
Northwest Behavioral Research Center
Roswell, Georgia, United States
Carman Research
Smyrna, Georgia, United States
Capstone Clinical Research, Inc.
Libertyville, Illinois, United States
Alpine Clinic
Lafayette, Indiana, United States
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States
Kennedy Krieger Institute
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Neurobehavioral Medicine Group
Bloomfield Hills, Michigan, United States
Rochester Center for Behavioral Medicine
Rochester Hills, Michigan, United States
Saint Charles Psychiatric Associates/Midwest Research Group
Saint Charles, Missouri, United States
Midwest Research Group
Saint Charles, Missouri, United States
Premier Psychiatric Research Institute, LLC
Lincoln, Nebraska, United States
Center for Emotional Fitness
Cherry Hill, New Jersey, United States
Village Clinical Research Inc.
New York, New York, United States
NYU School of Medicine
New York, New York, United States
Eastside Comprehensive Medical Center, LLC
New York, New York, United States
Finger Lakes Clinical Research
Rochester, New York, United States
Duke Child and Family Study Center
Durham, North Carolina, United States
Triangle Neuropsychiatry
Durham, North Carolina, United States
University of Cincinnati, Department of Psychiatry
Cincinnati, Ohio, United States
IPS Research Company
Oklahoma City, Oklahoma, United States
Paradigm Research Professionals
Oklahoma City, Oklahoma, United States
SummitResearchNetwork
Portland, Oregon, United States
Oregon Center for Clinical Investigations, Inc.
Portland, Oregon, United States
Oregon Center for Clinical Investigations, Inc.
Salem, Oregon, United States
Keystone Clinical Studies, LLC
Norristown, Pennsylvania, United States
Medical University of SC (MUSC)
Charleston, South Carolina, United States
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, United States
FutureSearch Clinical Trials, LP
Austin, Texas, United States
FutureSearch Trials of Dallas, LP
Dallas, Texas, United States
Pillar Clinical Research, LLC
Dallas, Texas, United States
Bayou City Research Corporation
Houston, Texas, United States
Clinical Trials of Texas, Inc
San Antonio, Texas, United States
Road Runner Research
San Antonio, Texas, United States
Family Psychiatry of the Woodlands
The Woodlands, Texas, United States
Neuropsychiatric Associates
Woodstock, Vermont, United States
NeuroScience, Inc
Herndon, Virginia, United States
Summit Research Network LLC
Seattle, Washington, United States
Dean Foundation for Health, Research and Education
Middleton, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Adler LA, Goldman R, Hopkins SC, Koblan KS, Kent J, Hsu J, Loebel A. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. Int Clin Psychopharmacol. 2021 May 1;36(3):117-125. doi: 10.1097/YIC.0000000000000333.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SEP360-301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.